CCR8 is a new therapeutic target in cutaneous T-cell lymphomas
暂无分享,去创建一个
R. Clark | T. Kupper | M. Bagot | M. Battistella | S. Mourah | N. Ortonne | A. Bensussan | J. Giustiniani | A. Marie-Cardine | H. Moins-Teisserenc | C. Ram-wolff | J. Bouaziz | A. de Masson | G. Dobos | Tiago Eustaquio | C. Ram-Wolff
[1] N. Siemers,et al. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models , 2021, Cancer Research.
[2] M. Bagot,et al. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases , 2021, European Journal of Dermatology.
[3] J. Cayuela,et al. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker , 2020, The British journal of dermatology.
[4] H. Kohrt,et al. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Conway,et al. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors , 2019, Clinical Cancer Research.
[6] B. Janela,et al. Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients. , 2019, The Journal of investigative dermatology.
[7] R. Clark,et al. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. , 2019, JCI insight.
[8] M. Bagot,et al. Association of autoimmunity and long‐term complete remission in patients with Sézary syndrome treated with mogamulizumab , 2018, The British journal of dermatology.
[9] C. Elmets,et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. , 2018, The Lancet. Oncology.
[10] K. Ladell,et al. CCR8 Expression Defines Tissue-Resident Memory T Cells in Human Skin , 2018, The Journal of Immunology.
[11] A. Janin,et al. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. , 2017, Blood.
[12] A. Kossenkov,et al. TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients. , 2017, The Journal of investigative dermatology.
[13] G. Plitas,et al. Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. , 2016, Immunity.
[14] K. Yanagihara,et al. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient , 2015, Annals of Hematology.
[15] D. Sasseville,et al. The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL) , 2015, Clinical Cancer Research.
[16] M. Goswami,et al. Reduction of Regulatory T Cells by Mogamulizumab, a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients with Aggressive/Refractory Mycosis Fungoides and Sézary Syndrome , 2014, Clinical Cancer Research.
[17] K. Uchimaru,et al. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T‐cell leukaemia‐lymphoma , 2013, British journal of haematology.
[18] J. Karbach,et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.
[19] R. Mansel,et al. Epidermis instructs skin homing receptor expression in human T cells. , 2012, Blood.
[20] R. Clark,et al. Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients , 2012, Science Translational Medicine.
[21] D. Sasseville,et al. Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma , 2010, Clinical Cancer Research.
[22] R. Biassoni,et al. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. , 2001, Blood.
[23] L. Michel,et al. CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells. , 2015, The Journal of investigative dermatology.